Deal Library / Pharma BD Deal Intelligence

Gastroenterology Deals

The Pharma Closeout tracks 42 deals, $542.3B in disclosed deal value, 31 with a post-close Outcome Score for Gastroenterology.

Median Critic Score: 78  ·  Median Outcome Score: 51

Best outcome: UCB SA / Celltech Group plc (92)  ·  Weakest outcome: Takeda Pharmaceutical Company Ltd. / Shire plc (8)

All 42 deals

• UCB SA / Celltech Group plc — 2004 · $2.7B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Centocor Inc. — 1999 · $4.9B · Worked — the deal delivered on its rationale.
• Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals — 2003 · $8.8B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Celgene Corporation — 2019 · $74.0B · Worked — the deal delivered on its rationale.
• Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) — 2013 · $3.2B · Worked — the deal delivered on its rationale.
• Gilead Sciences Inc. / CymaBay Therapeutics — 2024 · $4.4B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Telavant Holdings — 2023 · $7.1B · Largely worked — most objectives met.
• Pfizer Inc. / Arena Pharmaceuticals — 2021 · $6.7B · Largely worked — most objectives met.
• Celgene Corporation / Receptos Inc. — 2015 · $7.2B · Largely worked — most objectives met.
• Eli Lilly and Company / Morphic Holdings — 2024 · $3.2B · Largely worked — most objectives met.
• Actavis plc / Allergan, Inc. — 2014 · $70.5B · Largely worked — most objectives met.
• Roche Holding AG / 89bio Inc. — 2025 · $3.5B · Largely worked — most objectives met.
• AbbVie Inc. / Allergan, Inc. — 2019 · $63.0B · Largely worked — most objectives met.
• Abbott Laboratories / Solvay Pharmaceuticals — 2010 · $6.2B · Mixed — partial payoff, real shortfalls.
• Galmed Pharmaceuticals Ltd. / Colospan Ltd. — 2026 · $4M · Mixed — partial payoff, real shortfalls.
• Jazz Pharmaceuticals plc / Gentium S.p.A. — 2013 · $1.0B · Mixed — partial payoff, real shortfalls.
• Cubist Pharmaceuticals, Inc. / Adolor Corporation — 2011 · $415M · Mixed — partial payoff, real shortfalls.
• Valeant Pharmaceuticals / Salix Pharmaceuticals — 2015 · $15.8B · Underwhelmed — fell short of the thesis.
• Shire plc / Movetis NV — 2010 · $565M · Underwhelmed — fell short of the thesis.
• Lannett Company, Inc. / UCB S.A. (Kremers Urban Pharmaceuticals Inc.) — 2015 · $1.2B · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / Allergan, Inc. — 2015 · $160.0B · Did not work — the deal failed to deliver.
• Salix Pharmaceuticals Ltd. / Santarus Inc. — 2013 · $2.6B · Did not work — the deal failed to deliver.
• Salix Pharmaceuticals, Ltd. / Oceana Therapeutics, Inc. — 2011 · $300M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Galapagos NV — 2019 · $5.1B · Did not work — the deal failed to deliver.
• Forest Laboratories, Inc. / Aptalis Pharma Inc. — 2014 · $2.9B · Did not work — the deal failed to deliver.
• Shire plc / Lumena Pharmaceuticals, Inc. — 2014 · $260M · Did not work — the deal failed to deliver.
• Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. — 2017 · $1.2B · Did not work — the deal failed to deliver.
• Gilead Sciences, Inc. / Galapagos NV — 2016 · $2.1B · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / TiGenix NV — 2018 · $640M · Did not work — the deal failed to deliver.
• Eli Lilly and Company / Alnara Pharmaceuticals — 2010 · $380M · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Shire plc — 2018 · $62.0B · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Innovent Biologics, Inc. — 2025 · $11.4B
• GSK plc / Boston Pharmaceuticals Inc. — 2025 · $2.0B
• AbbVie Inc. / Celsius Therapeutics Inc. — 2024 · $250M
• AbbVie Inc. / Landos Biopharma Inc. — 2024 · $212M
• AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.7B
• Sanofi SA / Teva Pharmaceutical Industries Ltd. — 2023 · $1.5B
• Bayer AG / Mammoth Biosciences Inc. — 2022 · $1.0B
• Ipsen S.A. / GENFIT — 2021 · $543M
• AstraZeneca PLC / Allergan plc — 2020 · $250M
• Nestle S.A. / Allergan plc — 2020
• AstraZeneca plc / Allergan plc — 2016 · $1.5B

← Deal Library  ·  Interactive search  ·  How we score deals